The latest news from Arcinova
May 9, 2019
Contract Pharma: ‘A Modern CDMO’ article
Our Head of Drug Substance, Paul Quigley, recently shared his thoughts on the
May 6, 2019
Dr Stephen Byard receives Award for Service for outstanding volunteering efforts
Morpeth’s Dr Stephen Byard has received The Royal Society of Chemistry Aw
April 27, 2019
Industry Insights with… Paul Quigley
To coincide with CPhI North America 2019, we asked our Head of Drug Substance, Paul Quigley, to share his thoughts on the changing CDMO sector. The latest blog in our Industry Insights series high
April 26, 2019
Accelerating the path to first-in-human clinical trials
Our Head of Drug Substance, Paul Quigley, was recently interviewed by Outsourcing Pharma to coincide with his presentation at CPhI North America 2019. He explained the importance of ensuring rapid
April 17, 2019
Article: Chemistry 4.0 in pharmaceutical development
"The pharmaceutical industry is being revolutionised by the utilisation of digital technologies. Chemistry 4.0 describes this digital transformation and how its delivery is paving the way for the
April 16, 2019
Crédit d'impôt recherche (CIR) Grants Arcinova with R&D Organisation Status
Arcinova has been recognised and approved by the Crédit d'impôt recherche (CIR) as an organisation undertaking R&D activities. This will bestow significant benefits upon any French cus
April 8, 2019
Industry Insights with… Samuel Bourne
Welcome to the latest blog in our Industry Insights series, where we ask our experts to share their extensive expertise on topics within the pharmaceutical industry. We recently asked our Process
March 18, 2019
Article: Investigating multi-dimensional problems in drug substance development
"Finding solutions to the biggest challenges faced during drug substance development relies on properly integrating analytical and production expertise." Our CSO, Gareth
March 12, 2019